Thermo Fisher Scientific
THERMO FISHER SCIENTIFIC INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$44.6B
Operating marginCalculated
17.4%
Net assets to total assetsCalculated
48.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
17.4%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
3.2%
Capital efficiency
★★★☆☆position among all companies
12.6%
Revenue and profit
Performance, financial position and capital allocation
Thermo Fisher Scientific
Recent performance trends
Thermo Fisher Scientific
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$39.2 billion | US$44.9 billion | US$42.9 billion | US$42.9 billion | US$44.6 billion |
| Operating income | US$10.0 billion | US$8.4 billion | US$6.9 billion | US$7.3 billion | US$7.7 billion |
| Net income | Could not be retrieved | Could not be retrieved | US$6.0 billion | US$6.3 billion | US$6.7 billion |
| Total assets | US$95.1 billion | US$97.2 billion | US$98.7 billion | US$97.3 billion | US$110.3 billion |
| Shareholders' equity | US$40.8 billion | US$44.0 billion | US$46.7 billion | US$49.6 billion | US$53.4 billion |
| Net cash provided by (used in) operating activities | US$9.3 billion | US$9.2 billion | US$8.4 billion | US$8.7 billion | US$7.8 billion |
| Net cash provided by (used in) investing activities | US$-21.9 billion | US$-2.2 billion | US$-5.1 billion | US$-5.8 billion | US$-4.0 billion |
| Net cash provided by (used in) financing activities | US$6.6 billion | US$-2.8 billion | US$-3.6 billion | US$-6.8 billion | US$1.8 billion |
| Cash and cash equivalents | US$4.5 billion | US$8.5 billion | US$8.1 billion | US$4.0 billion | US$9.9 billion |
Revenue scale in the same industry
Thermo Fisher Scientific
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificThis companyFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 40 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$1.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$9.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$1.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-4.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$7.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.1 billion | Consolidated | Disclosed |
| Dividends paid | US$0.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$53.4 billion | Consolidated | Disclosed |
| Non-controlling interests | US$7.00 million | Consolidated | Disclosed |
| Net assets | US$53.4 billion | Consolidated | Disclosed |
| Net sales | US$44.6 billion | Consolidated | Disclosed |
| Operating income | US$7.7 billion | Consolidated | Disclosed |
| Net income | US$6.7 billion | Consolidated | Disclosed |
| Total assets | US$110.3 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$3.0 billion | Consolidated | Disclosed |
| Operating margin | 17.4% | Consolidated | Calculated |
| Net assets to total assets | 48.4% | Consolidated | Calculated |
| Net margin | 15.0% | Consolidated | Calculated |
| Return on equity | 12.6% | Consolidated | Calculated |